Abstract
Background: Concurrent radiochemotherapy has been established as a treatment standard for patients with inoperable non-small cell lung cancer (NSCLC) since the 1990s. There are potential synergistic effects between radiochemotherapy and immunotherapy. Thus, immune checkpoint inhibitors are increasingly used in patients with metastatic tumors. Objectives: What is the role of radioimmuntherapy in patients with stage III NSCLC? Materials and methods: A semistructured literature search was performed. Results: In this review, the established radiochemotherapy and the current data regarding potential synergisms between radiotherapy and immunotherapy are summarized. In this context, consolidation immunotherapy with durvalumab after chemoradiation offers a significant overall survival benefit as shown by the PACIFIC trial. Conclusion: Immunotherapy with durvalumab as consolidation therapy after concurrent radiochemotherapy represents a new paradigm for patients with stage III NSCLC. This could lead to a rearrangement of the current treatment algorithms for patients with stage III NSCLC, also with respect to surgery. While long-term data are still pending, further clinical studies are currently testing the role of immunotherapy in patients with stage III NSCLC.
| Translated title of the contribution | Locally advanced non-small cell lung cancer: radioimmunotherapy as new standard of care? |
|---|---|
| Original language | German |
| Journal | Pneumologe |
| Volume | 16 |
| Issue number | 6 |
| Pages (from-to) | 366-372 |
| Number of pages | 7 |
| ISSN | 1613-5636 |
| DOIs | |
| Publication status | Published - 01.11.2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Locally advanced non-small cell lung cancer: radioimmunotherapy as new standard of care?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver